Literature DB >> 21818111

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.

G Metzgeroth, P Erben, H Martin, S Mousset, M Teichmann, C Walz, T Klippstein, A Hochhaus, N C P Cross, W-K Hofmann, A Reiter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21818111     DOI： 10.1038/leu.2011.181

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer.

Authors:  Jill K Jones; Eric M Thompson
Journal:  Mol Cancer Ther       Date:  2020-06-30       Impact factor: 6.261

Review 2.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

Review 3.  Chronic myeloid leukemia: a type of MPN.

Authors:  Muhammad Ammar Samad; Eman Mahboob; Hussain Mansoor
Journal:  Blood Res       Date:  2022-05-30

4.  F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.

Authors:  S P Gorantla; K Zirlik; A Reiter; C Yu; A L Illert; N Von Bubnoff; J Duyster
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

5.  A proposal regarding reporting of in vitro testing results.

Authors:  Malcolm A Smith; Peter Houghton
Journal:  Clin Cancer Res       Date:  2013-04-11       Impact factor: 12.531

6.  Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.

Authors:  Krisna C Duong-Ly; Karthik Devarajan; Shuguang Liang; Kurumi Y Horiuchi; Yuren Wang; Haiching Ma; Jeffrey R Peterson
Journal:  Cell Rep       Date:  2016-01-14       Impact factor: 9.423

Review 7.  Novel targeted therapies for eosinophil-associated diseases and allergy.

Authors:  Susanne Radonjic-Hoesli; Peter Valent; Amy D Klion; Michael E Wechsler; Hans-Uwe Simon
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-17       Impact factor: 13.820

8.  Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.

Authors:  Andreas Hochhaus; Philipp D le Coutre; Hagop M Kantarjian; Michele Baccarani; Philipp Erben; Andreas Reiter; Tracey McCulloch; Xiaolin Fan; Steven Novick; Francis J Giles
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-22       Impact factor: 4.553

9.  The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.

Authors:  Yingying Shen; Xiaoke Shi; Jingxuan Pan
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

10.  Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.

Authors:  Yanli Jin; Ke Ding; Honglin Li; Mengzhu Xue; Xiaoke Shi; Chengyan Wang; Jingxuan Pan
Journal:  Mol Cancer       Date:  2014-01-28       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.